Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07543120 · ClinicalTrials.gov registry record · Phase 2
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 323
- Enrollment target
NCT07543120 is a Phase 2 study that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 323 participants.
The verdict
NCT07543120, a Phase 2 study, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 323 participants
- Enrollment target
Study Summary
The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.
Interventions
- DRUG QCZ484
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2026-05-07 |
| Est. Completion | 2031-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07543120
The ClinicalTrials.gov registry entry for NCT07543120 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QCZ484 is the first listed.
NCT07543120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07543120 about?
NCT07543120 is a clinical study titled "An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.". The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.
What is the current status of trial NCT07543120?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 323 participants. The study started on 2026-05-07. Estimated completion is 2031-11-30.
What interventions are being tested in trial NCT07543120?
The interventions under investigation include: QCZ484 (DRUG).
Who is sponsoring clinical trial NCT07543120?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.